RxDoctor Payments Data

Nhu Truong, MD

Family Medicine · Garden Grove, CANPI 1508824368

Payments from drug & device makers

$2,108in general payments, 2019–2025

Across 37 payments — averaging $56.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$386
  • Lilly USA, LLC$368
  • Gilead$299
  • Nestle Healthcare Nutrition Inc.$193
  • Aimmune Therapeutics, Inc.$191
  • Sanofi$126
  • plus $546 from 7 others

What the payments were for

  • Travel & lodging$10%
  • Food & beverage$2,107100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,108 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$128,412
Medicare patients
246
Services billed
1,172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase71$109,735
CreonLipase/Protease/Amylase77$90,579
EliquisApixaban116$77,581
JanuviaSitagliptin Phosphate85$60,982
LinzessLinaclotide60$46,036
VascepaIcosapent Ethyl118$37,196
Diclofenac Sodium91$35,371
Memantine Hcl ErMemantine Hcl209$29,223
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$24,215
Dexlansoprazole DrDexlansoprazole78$22,650
JardianceEmpagliflozin15$14,564
MyrbetriqMirabegron18$12,577
Celecoxib440$11,819
TrulicityDulaglutide29$11,513
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$10,958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis$117$145,393149 claims
Aimmune Therapeutics, Inc.Zenpep$191$109,73571 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$124$35,49584 claims
Lilly USA, LLCTrulicity$368$11,51329 claims
AstraZenecaBreztri Aerosphere$386$10,95819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Garden Grove

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →